Compugen Reports Fourth Quarter and Full Year 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500, Nasdaq set for lower open as AI stocks slide on debt concerns
- U.S. producer prices rise by 1.3% month-on-month in September
- Oil prices slips as US weighs easing sanctions on 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Walmart stock: Deutsche Bank gets bullish amid pricing tailwinds
- Nebius shares sink on CoreWeave's bond yield spike and insider sales
- IonQ prices $2 billion equity offering at $40 per share
- Rocket Lab delays Neutron rocket debut to 2027
- Bloom Energy stock falls as inflation data pressures markets
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
Rodman & Renshaw Reiterates Buy Rating on Compugen (CGEN)
March 4, 2025 10:26 AM ESTRodman & Renshaw analyst Tony Blair reiterated a Buy rating and $4.00 price target on Compugen (NASDAQ: CGEN).
The analyst comments "This morning, before the market opened, Compugen Ltd. (CGEN; Buy) released its business updates for 4Q24. The company reported an ending cash balance of $103.3 million for the quarter, which is expected to provide funding into 2027. CGEN remains on track to initiate a randomized adaptive platform trial in 2Q25 to... More



